



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.06
Trade Time:	11:08 AM ET 10/18/17
Change:	0.05 ↑ (2.488%)
Day Range	2.01 - 2.09
52-Week Range	1.27 - 7.10
Volume	136,225


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 10/13/17**
[Rexahn Announces \\$8 Million Registered Direct Offering](#)
- 10/10/17**
[Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117](#)
- 09/21/17**
[Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC](#)
- 09/11/17**
[Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)
- 09/10/17**
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- 02/24/17**
[Annual Report \(10-K\)](#)
- 02/24/17**
[Proxy Statement \(DEF 14A\)](#)
- 08/04/17**
[Quarterly Report \(10-Q\)](#)
- 05/03/17**
[Quarterly Report \(10-Q\)](#)
- 11/04/16**
[Quarterly Report \(10-Q\)](#)